Serpin Pharma Awarded Competitive NCI Grant for SP16
The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy. The Principal Investigators are Serpin Pharma's CEO and Executive Chairperson, Dr. - September 20, 2022
Press Releases 1 - 1 of 1